• ISSN 2320-0901 (Online)
  • Monthly since 2012
  • Open access
  • Double blind peer review
editor@ijrmp.org

Subjects

  • Gap Assessment Frameworks for Post-Approval Regulatory Compliance

    Post-approval regulatory compliance remains a cornerstone of pharmaceutical quality assurance, ensuring that products on the market continuously adhere to evolving safety, efficacy, and quality standards. Following initial market authorization, manufacturers face myriad challenges: real-world safety signal…

  • The Role of Regulatory Affairs in Lifecycle Management of Generic Drugs

    The lifecycle management of generic drugs encompasses the continuum of activities from initial regulatory submission through post-marketing surveillance, product variation, and eventual discontinuation. Regulatory affairs (RA) professionals serve as strategic linchpins, interpreting evolving guidelines, coordinating cross-functional…

  • Cross-Functional Collaboration Models in Regulatory Project Execution

    Cross-functional collaboration is an essential strategic approach employed by life sciences organizations to address the increasing complexity of regulatory requirements and compress ever-tightening submission timelines. While traditional siloed structures impede information flow and prolong decision cycles,…

  • Developing Standard Operating Procedures for Global Dossier Compilation

    Developing robust Standard Operating Procedures (SOPs) for global dossier compilation is a foundational element in ensuring both regulatory compliance and operational excellence within multinational pharmaceutical and biotechnology organizations. In the rapidly evolving landscape of global health…

  • Impact of Regulatory Delays on Product Launch Timelines: A Risk-Based Study

    — Regulatory approval processes are critical checkpoints in the lifecycle of new products, yet delays in these processes can significantly impede time to market, impacting organizational competitiveness and revenue streams. This study adopts a risk-based perspective…

  • Automation in Regulatory Document Compilation for ANDA Submissions

    — The submission of an Abbreviated New Drug Application (ANDA) to regulatory agencies such as the U.S. Food and Drug Administration (FDA) necessitates the assembly of extensive technical, scientific, and administrative documentation. Traditionally, this process has…

  • Designing Regulatory Intelligence Dashboards for Pharma Portfolio Management

    In the contemporary pharmaceutical environment, regulatory landscapes shift rapidly, driven by evolving guidelines, novel health crises, and geopolitical factors. Traditional compliance tracking—often reliant on manual spreadsheets and disparate internal portals—can no longer keep pace with the…

  • Comparative Analysis of FDA and EMA Requirements for Generic Drug Approvals

    — Generic medicines now anchor national cost-containment strategies worldwide, yet filing pathways remain subject to region-specific statutory mandates and administrative cultures. Building on existing scholarship, this study deepens the comparative lens by triangulating newly published guidance…

  • Project Risk Mitigation Strategies in Regulatory Affairs Operations

    — Regulatory Affairs (RA) functions have become pivotal strategic partners in biopharmaceutical value chains, yet they routinely grapple with volatile regulatory landscapes, compressed commercial-launch horizons, and ever-growing documentation complexity. Conventional project-management frameworks often fail to reflect…

  • Regulatory Submission Lifecycle Management in the Global Pharmaceutical Industry

    — Efficient regulatory submission lifecycle management (RS-LCM) has become a strategic imperative for pharmaceutical companies amid accelerating global product pipelines and increasingly complex regional regulations. This manuscript explores contemporary RS-LCM practices, focusing on electronic Common Technical…